A carregar...
Beyond DNA repair: the novel immunological potential of PARP inhibitors
Loss of excision repair cross-complementation group 1 (ERCC1), frequently found in lung cancer, and mutations in breast cancer type 1/2 susceptibility genes (BRCA1/2), often found in ovarian, breast and prostate cancers, confer sensitivity to poly-(ADP-ribose) polymerase inhibitors (PARPi). Our work...
Na minha lista:
| Publicado no: | Mol Cell Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6512907/ https://ncbi.nlm.nih.gov/pubmed/31131303 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2019.1585170 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|